Topics:
Lung Cancer • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Non-small cell lung cancer • Ohio State University • NCI-CCC Thoracic Tumor Board Question
How would you treat a patient with squamous NSCLC with NRG1 amplification (no fusion) who has progressed on first-line treatment?
Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear.
Answer from: Medical Oncologist at Community Practice
NRG1 amplification may be associated with NRG1 fusions, but can also occur without fusion. The occurrence is rare and therapeutic outcomes have not been described in the same way as they have been with NRG1 fusion. Given the differing mechanisms and unclear therapeutic benefit, I would not use afati...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Zenocutuzumab appears to be tumor agnostic per early data.